Want to see HK:9960 full AI Analyst Report?
Kindstar Globalgene Technology, Inc. (9960) AI Stock Analysis
Top Page
Kindstar Globalgene Technology, Inc.
(HKEX:9960)
Overall score reflects a pressured core business (multi-year revenue decline and continued net losses) partially offset by a low-leverage balance sheet and a notable improvement to positive operating and free cash flow in 2025. Technicals remain bearish with the price below key moving averages and a negative MACD, while valuation is supported mainly by the high dividend yield despite loss-driven negative P/E.
Kindstar Globalgene Technology, Inc. (9960) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 891.47M
- Dividend Yield
- 10.61%
- Average Volume (3M)
- 268.65K
- Price to Earnings (P/E)
- -18.6
- Beta (1Y)
- 0.54
- Revenue Growth
- 7.95%
- EPS Growth
- 60.86%
- Country
- Hong Kong
- Employees
- 2,999
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Kindstar Globalgene Technology, Inc. Business Overview & Revenue Model
Company Description
Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical dru...
How the Company Makes Money
Kindstar Globalgene Technology, Inc. primarily makes money by providing fee-based clinical specialty testing services to healthcare institutions (e.g., hospitals) and other customers that outsource laboratory testing. Revenue is generally generated w...
Kindstar Globalgene Technology, Inc. Financial Statement Overview
Summary
Mixed fundamentals: revenue has contracted for three consecutive years and the company remains loss-making (net margin ~-6% in 2024–2025), which weighs heavily. Offsetting this, the balance sheet is conservatively levered (debt-to-equity ~0.16) and 2025 cash flow improved to positive operating cash flow and free cash flow, though longer-term cash flow consistency is not yet proven.
Income Statement
36NegativeBalance Sheet
70PositiveCash Flow
48Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 950.26M | 933.57M | 927.57M | 967.26M | 1.39B | 930.67M |
| Gross Profit | 432.87M | 411.38M | 439.56M | 451.13M | 603.05M | 485.77M |
| EBITDA | -44.87M | -69.21M | -90.49M | 126.38M | 150.72M | -1.39B |
| Net Income | -41.53M | -58.74M | -54.59M | 41.29M | 75.46M | -1.45B |
Balance Sheet | ||||||
| Total Assets | 3.71B | 3.76B | 3.77B | 3.67B | 3.73B | 3.19B |
| Cash, Cash Equivalents and Short-Term Investments | 1.80B | 1.56B | 1.66B | 2.03B | 2.00B | 2.15B |
| Total Debt | 394.97M | 438.12M | 398.36M | 194.29M | 199.86M | 18.19M |
| Total Liabilities | 1.07B | 969.17M | 950.51M | 774.23M | 871.62M | 464.15M |
| Stockholders Equity | 2.58B | 2.73B | 2.78B | 2.87B | 2.83B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | 138.39M | 43.60M | -179.57M | -189.65M | -102.90M | -220.23M |
| Operating Cash Flow | 182.33M | 91.17M | -44.12M | -14.78M | 21.41M | 68.03M |
| Investing Cash Flow | -112.63M | -36.85M | -1.21B | 854.92M | -1.35B | -666.06M |
| Financing Cash Flow | -131.87M | -39.49M | 144.63M | -82.83M | 97.64M | 1.59B |
Kindstar Globalgene Technology, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9960, the sentiment is Negative. The current price of 0.90 is below the 20-day moving average (MA) of 0.91, below the 50-day MA of 0.93, and below the 200-day MA of 1.00, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 46.11 is Neutral, neither overbought nor oversold. The STOCH value of 75.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:9960.
Kindstar Globalgene Technology, Inc. Peers Comparison
Overall Rating
HK:661874Outperform
HK:607862Neutral- HK:996051Neutral
HK:195145Neutral
HK:245343Neutral
HK:388641Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6618 | 74Outperform | HKD 121.56B | 16.84 | 10.15% | ― | 25.80% | 35.81% |
| HK:6078 | 62Neutral | HKD 5.84B | 27.81 | 2.55% | ― | 1.59% | -58.55% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| HK:9960 | 51Neutral | HKD 931.99M | -18.57 | -1.56% | 10.61% | 7.95% | 60.86% |
| HK:1951 | 45Neutral | HKD 6.11B | 26.75 | 1.87% | 1.84% | 6.52% | ― |
| HK:2453 | 43Neutral | HKD 489.79M | -2.69 | -8.65% | ― | 47.93% | 65.94% |
| HK:3886 | 41Neutral | HKD 1.10B | 78.09 | 0.48% | 1.10% | -3.26% | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:9960 | Kindstar Globalgene Technology, Inc. | 0.90 | -0.30 | -25.42% | |
| HK:1951 | Jinxin Fertility Group Ltd. | 2.27 | -0.16 | -6.47% | |
| HK:3886 | Town Health International Medical Group Ltd. | 0.16 | -0.11 | -40.07% | |
| HK:6078 | Hygeia Healthcare Holdings Co., Ltd. | 9.51 | -3.88 | -29.01% | |
| HK:6618 | JD Health International, Inc. | 38.10 | -23.90 | -38.55% | |
| HK:2453 | Concord Healthcare Group Co., Ltd. Class H | 0.63 | -1.81 | -74.39% |
Kindstar Globalgene Technology, Inc. Corporate Events
Kindstar Globalgene Narrows Loss as Oncology Testing Drives Interim Growth
Kindstar Globalgene Technology reported interim revenue of RMB473.6 million for the six months ended June 30, 2026, a 3.7% year-on-year increase driven by stable performance in its core hematology segment and rapid expansion in oncology testing. The...
Kindstar Globalgene Sets Board Meeting to Review Interim Results and Dividend
Kindstar Globalgene Technology, Inc. has scheduled a board meeting for August 26, 2026 to review and approve the group’s consolidated interim results for the six months ended June 30, 2026. The board will also consider the payment of an interim...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026